

Recent Update on Advanced Drug Delivery System

Swapnila Roy^{1,*}

Abstract

Over the past decade, there has been a growing interest in the use of artificial intelligence (AI) technology for analysing and interpreting biological or genetic data, accelerating drug discovery, and identifying selective small-molecule modulators or rare molecules in addition to predicting their behaviour. The use of artificial neural networks (ANNs) for the rapid analysis of massive amounts of data, the development of novel hypotheses and treatment plans, the prediction of disease progression, and the assessment of the pharmacological profiles of drug candidates may significantly enhance treatment outcomes. By gathering in the particular cancer areas, diagnostic tests utilizing nanoparticles (NPs) allow biomarker identification and guarantee precise medication delivery planning. AI and NPs for cancer targeting may be used to create sophisticated algorithms that better categorise different cancers and comprehend complicated disease patterns. This is so that treatment outcomes may be improved. AI offers enormous possibilities for automation, quicker patient interpretation of complicated illness information, and faster processing of complex medical data. Nano medicine and nano transport systems are rapidly developing technological know-how, in which materials in small range are subjected to function method of diagnostic gear or to supply healing agents to precise focused web sites in a controlled manner. Nanotechnology presents one-of-a-kind blessings in treating chronic human sicknesses by website-precise and goal-oriented delivery of specific medicines. There are numerous applications of nano medicine (chemotherapeutic retailers, organic agents, immunotherapeutic agents etc.) in the treatment of numerous illnesses. This review emphasizes how AI may assist in logically converting clinical data into useful insights for cancer treatment advanced drug delivery systems in different diseases and approval process for drug devices in India, EU and USA.

Keywords: Artificial intelligence (AI), cancer, rheumatoid arthritis, diabetes, nanoparticles, drug devices' approval process eumatoid

INTRODUCTION

Drug delivery systems can be labeled into one-of-a-kind approaches based on the path of management bodily and chemical differences among wholesome and microenvironment of diseased tissues gives clever design of stimuli caused drug debris. The development of progressive formulations like drug particle length design (nano-to millimeters), micro-to nano-encapsulated drug debris, and microchambers that improve the water solubility and bioavailability of medicine is a sizable thing of modern drug shipping era. Generally, drug shipping methods do not involve chemical change of the lively factor. These methods consist of solubilization, permeability enhancement, and different special drug shipping mechanisms, such as focused shipping, decreased nearby irritation, and drug-device combination [1]. This overview deals with those new vendors and their development in drug shipping. Drug transport strategies live unchanged inside the direction of the

*Author for Correspondence

Swapnila Roy
E-mail: swapnilaroy@gmail.com

¹Associate Professor, Lingaya's Vidyapeeth Deemed-to-be-University, Faridabad, Haryana, India

Received Date: November 26, 2023
Accepted Date: December 12, 2023
Published Date: January 06, 2024

Citation: Swapnila Roy. Recent Update on Advanced Drug Delivery System. International Journal of Advance in Molecular Engineering, 2023; 1(1): 22–30p.

simple pharmacodynamic properties of a pharmaceutical compound, however they will change its pharmacokinetic homes to affect its pharmacodynamic overall performance. For every drug development and subsequent regulatory evaluation, a favored drug purpose product profile (DTPP) needs to be properly stated. It is noteworthy that some drug shipping structures carried out regionally can also offer systemic publicity which may additionally or may not be perfect, in addition, remarkable from neighborhood transport, targeted delivery is every other way to acquire the cause of maximizing the nearby drug exposure and minimizing systemic factor impact, additionally, the designing chemical compounds with excessive selectivity and immunotherapy, drug delivery structures together with nanomedicines and antibody-drug conjugates (ADC) were efficaciously executed for some advertised capsules [2]. New drug shipping structures consist of lipidic, proteic and polymeric technology to offer new sustained drug shipping with higher body distribution, drug safety from harsh outside surroundings and avoidance of drug clearance. Many modern technology for effective drug transport had been advanced, along side implants, nanotechnology, cell and peptide encapsulation, microfabrication, chemical trade and others. Research on AI-enabled computational approaches for drug development and other pharmaceutical research has grown significantly in the biomedical field, as has other pharmaceutical research [3]. AI has a significant impact on pharmaceutical operations such as chemical identification, productivity improvement, regulatory compliance assurance, data transformation, scalability and optimisation. In recent years, researchers have focused on developing and deploying microrobotics in the medical field. These nanomachines perform a variety of medicinal duties, including drug delivery in situ, disease cell membrane targeting, and even microsurgeries. Although nanorobots face persistent challenges in terms of material design, production, availability, and biocompatibility, research indicates their enormous potential [4].

In this review application of artificial intelligence for RA, DM and cancer as well as AI in nanomedicine and nanorobots in drug delivery system will be discussed.

Therefore, the study's main goal is to draw attention to the most current developments in drug delivery system and also to demonstrate how using AI, and nanomedicine as well as nano robots together might assist overcome some of the current problems with medication delivery (Figure 1).




Figure 1. The diagram illustrates several AI approach domains and the subfields within them that may be used to various areas of drug discovery and development [5].

Advanced Drug Delivery System in Different Diseases

To triumph over the regulations of traditional drug shipping structures, pharmaceutical organizations targeted at the design and construction of innovative medication delivery systems. The compelling improvements in patient compliance, medical efficacy, prolonged product life through a controlled medication launch, and financial additions like lower frequency and management expenditure reductions are what drive the need for excessive common performance, flexibility, and managed release systems. For this reason, novel drug shipping structures might be maximum of the fastest growing segments within the drug enterprise. Novel drug shipping structures are engineered in line with a proper format to decorate the delivery and the performance of present drugs with appreciate to standard structures [5]. If you wish to target, manage, and adjust the distribution of medicine, novel drug shipping structures combine cutting-edge procedures and new dosage bureaucracy in comparison to classic ones. By using the evolution of a drug from a conventional to a completely unique drug transport gadget the performance concerning efficacy, protection and affected person compliance can be remarkably progressed. The delivery of the medication to the specific target site at a rate and extent according to the needs of the body and the prompt monitoring of the active unit during the course of therapy are the two conditions that innovative drug organisations attempt to meet. Amid the one of a kind novel drug delivery systems, fast dissolving drug transport systems have received excellent importance concerning oral course of control. To start with evolved as alternative to pills, drugs and syrups for pediatric and geriatric patients with the concern of suffocation, speedy dissolving drug transport structures have the primary advantage of a brief disintegration or dissolution within the salvia without the want of greater liquid. Self-emulsifying drug delivery systems are one method among several for increasing the oral bioavailability of hydrophobic tablets. They also have a great personal capability. Some drug delivery systems are nanoparticulate drug transport structures, vesicular drug transport systems, self-emulsifying drug shipping systems. Here the drug delivery systems of RA, DM and Cancer will be discussed.

Rheumatoid Arthritis(RA)

Immune reactions in rheumatoid arthritis cause the breakdown of developing cartilage and bones as well as the release of rheumatoid components. Each the environmental factors and genetic elements are implicated within the progress of scientific indication of RA. Currently available remedy for rheumatoid arthritis includes several NSAIDs(Non-steroidal anti-inflammatory drugs),Glucocorticoids, DMARDs(ailment-modifying antirheumatic tablets), organic anti-rheumatic capsules. The main problems with the conventional RA medication dose were poor patient compliance, a short half-life, low bioavailability, and inadequate solubility. All of which is probably resolved with the aid of seeking out novel dosage procedures. By delivering the medication to the intended area with more awareness, microparticles, nanoparticles, nanodispersions, nanocapsules, nanoemulsions, nanosuspensions, and other innovative shipping mechanisms for RA therapies increase therapeutic effectiveness.

Diabetes Mellitus

Because of the complication in the pathogenesis of diabetes mellitus, the crux to govern and treatment diabetes mellitus is mixed with the patients' character instances to make self-control including eating routine change, appropriate workout, glucose near monitoring, temper assessment, and drug treatment in mixture. To date, because of the development and advances of medicine remedy, the clinical treatment of diabetes has made top notch development and the circumstance of sufferers with diabetes has been nicely controlled. With the in-depth have a look at the characters of diabetes mellitus, the exploration of novel antidiabetic pills has been steadily broadened, now not most effective paying extremely good interest to the brand new objectives of non-insulin hypoglycemic capsules and the improvement and usage of nano businesses, moreover actively seeking out remedies which might be predicted to sincerely therapy diabetes mellitus, which includes gene remedy and stem mobile remedy.

AI AND NANO MEDICINE-BASED IMPLICATION IN DIFFERENT DISEASES

Rheumatoid Arthritis(RA)

In medicine and healthcare, research into the prospective applications of artificial intelligence (AI), including machine learning (ML) and deep learning (DL) techniques, is a rapidly expanding field. Patients with chronic rheumatological diseases lacking an optimal treatment, such as rheumatoid arthritis (RA), the second most prevalent autoimmune disease, may require these techniques to receive high-quality care. AI algorithms can help with patient detection within electronic health records (EHR), phenotyping, treatment response assessment, monitoring disease course, determining prognosis, novel drug discovery, and advancing basic science research [6]. They can also help with screening and identification of susceptible groups, diagnosis using omics, imaging, clinical, and sensor data, and prognosis determination. In patients with RA, they may also help with risk assessment for the development of comorbidities, such as cardiovascular illnesses.

Diabetes Mellitus (DM)

Automatic retinal screening, clinical diagnostic assistance, patient self-management tools, and risk stratification are the four key areas where clinical AI applications are being made in the diagnosis and treatment of diabetes. The first category is automated retinal screening, which uses artificial intelligence to automatically determine if diabetic retinopathy—a serious consequence of diabetes—is present or absent from fundus pictures. Without the expert opinion of an ophthalmologist, individuals might be identified with diabetic retinopathy or without it with an AI gadget. The second category is diagnostic clinical support. Rather than just a support system for diabetes diagnosis, artificial intelligence technologies that emulate the "hidden tips of treatments by a specialist," such as fine-tuning insulin dose, are being developed at present. The third category is self-management tools for patients.

Prediction and risk stratification are the last two categories of AI employment in the diagnosis and management of diabetes [7].

Cancer

A wide spectrum of diseases that result from the change of normal cells into tumour cells and develop through several stages from malignant lesions to malignancy are collectively referred to as cancer. For localized cancer, the standard course of treatment is surgery; for advanced cancer, it entails radiation therapy and chemotherapy [8]. As a result, a new generation of cancer therapeutics has emerged during the last several years, including targeted cancer therapies for increased treatment precision. Recently, localised medication administration for specific tumor areas and assistance as a diagnostic tool have both been made possible by nanomedicine and nano-delivery systems [2]. As natural substances are currently being researched for treating cancer and various other microbial and inflammatory illnesses, nanotechnology is essential in creating new medication delivery methods. As there are several cancer indicators and each patient has a unique molecular profile, treating cancer is difficult. This variety is evident in many cancer types because individuals' particular genetic fingerprints and driver mutations cause tumour heterogeneity, a significant hurdle in the treatment of cancer. In more recent years, research has focused on developing patient-specific disease profiles using diagnostic nanoparticles, such as quantum dots (QDs), gold nanoparticles (AuNPs), and polymer dots (PDs) [9]. These patient-specific disease profiles can then be used to develop personalized patient treatments and advance precision medicine. A rare opportunity exists to fully use AI's potential in precision medicine for the detection and treatment of cancer, thanks to recent advancements in the field and its potential contribution to bionanotechnology

AI-BASED OPTIMISATION OF MEDICINE DISCOVERY AND DELIVERY

The use of AI approaches is constantly being suggested to address different issues in nanotechnology. creating nanosystems, nanocomputing, and AI techniques in creating principles of nanoscale simulation are the important themes, with an emphasis on minimizing computational time and effectively estimating, predicting, and simulating system parameters [10].

In this context, appropriate options are investigated for AI-based optimisation for combination medication delivery employing several NP classes to improve drug localization at the tumour site. In cancer treatment, doctors often deal with individuals' different genetic profiles, which may include several molecular abnormalities. Various factors, including pharmacological characteristics and biological parameters, are taken into account for drug administration while treating a cancer patient. To guarantee passage, penetration, and reaching the intended region represented by tissue or cellular membranes, targeted drug delivery systems must consider a variety of criteria, such as the proper drug administration. To detect interactions between the biological environment and medicine and its molecular characteristics in this respect, a sophisticated knowledge of the biological environment is necessary. AI has shown enormous promise in pharmacokinetics assessments with complicated inputs including drug interactions, phenotypic information, chemical interactions, and even genetic data to customize medication administration in order to grasp the biological interactions involving membranes.

NANO PARTICLE BASED DRUG DELIVERY TECHNOLOGY

Cancer biomarkers are essential in oncology because they provide vital data for risk assessments, prognosis, treatment response identification, accurate disease diagnosis, and effective disease progression monitoring (Figure 2).

Consequently, biomarker information aids clinicians in selecting the optimal cancer treatment for patients. In addition, biomarkers differ between patients; therefore, identifying the patient's unique molecular signature facilitates the screening of cancer patients for cancer therapy. Recently, a variety of biomarker tests have been conducted to assist in selecting the most suitable cancer treatment for the patient. The majority of biomarker assays identify genetic markers, proteins, or other tumour markers. The most crucial point to remember when talking about drug delivery, especially for cancer therapies, is to distribute the targeted medications precisely so that they only activate at the intended tumour location and do not harm healthy tissues close to the organ of interest. Additionally, ligand-, antibody-, or other cellular marker-coated drug-loaded NPs can attach to the target cells, enhancing the therapeutic response. For biomarker sensing applications, a variety of nanomaterials are used, including carbon nanotubes, gold nanoparticles, and quantum dots. With their great sensitivity and specificity, nanoparticles are now the most promising cancer biomarker sensing technology. To advance diagnostic and therapeutic platforms, the use of nanomaterials in *in vivo* and *in vitro* medical applications is presently being studied. NPs are adaptable candidates that are often used in biological applications, such as their roles in improving radiotherapy, medication administration, and diagnostic tests. Additionally, cutting-edge NPs-based systems are being investigated for improved cancer medication penetration and body monitoring to allow effective cancer treatment with lower risks compared to traditional ways.

PROBLEMS IN CANCER IMAGING TODAY THAT CAN BE SOLVED USING NPS AND AI

For clinical reporting and treatment planning, a comprehensive understanding of the illness, including exams, image post-processing, and interpretation, is required for high-quality cancer imaging. The imaging methods are focused on identifying cancer entities and metastatic patterns as well as gathering additional clinical data from multiple imaging modalities to evaluate the tumor's response to treatments, identify problems, and rule out the possibility of a tumour recurrence. Molecular imaging and drug delivery have been combined in recent developments to see the drug delivery process in real-time and understand the *in vivo* effectiveness of medicinal medicines. Researchers intend to develop a multifunctional theragnostic instrument for targeted drug delivery, which will aid in molecular imaging and controlled drug release for optimal therapeutic response. Although there has been little investigation into these possibilities, medical imaging is crucial in assessing drug delivery systems based on nanomedicine. By incorporating imaging into drug administration, researchers hope to learn more about pharmacokinetics, biodistribution, and drug accumulation at the location of the targeted tumour. The permeability and retention effect (EPR),

which has large degrees of variability in cancer patients, is confirmed by these imaging results on nanomedicine absorption levels at the tumour location. A nanoparticle tracking analysis (NTA) system, for instance, was created by Malvern Panalytical to visualise and gauge various sizes and drug concentrations. To define labelled particles, this programme computes hydrodynamic diameters using fluorescence modes. Additionally, a streamlined method of characterising and validating real-time monitoring of the nanoparticle population is available. Therefore, in order to correctly discern and exactly estimate the size of the particle, including its reflective index, holographic pictures of single particles were analysed using a convolutional neural network (CNN). This was done to create a label-free approach to concurrently measure the sizes of nanoparticles and deliver the subwavelength particles [11].




Figure 2. A hypothetical AI-enabled biomarker sensing method is shown graphically [11].

Targeted medication administration represents a significant advance in cancer treatment, but its success can only be assured if biomarker-sensing nanoparticles can assist in early disease detection and provide prognostic information. Artificial intelligence (AI) is used in this case to help generate an appropriate treatment plan by evaluating all the complicated heterogeneous tumour information and patterns gathered by biomarker sensing NPs. It also helps in the quicker detection of mutations, classifying mutated and non-mutated biomarkers, improving drug and protein interactions for greater drug efficacy, and improving drug delivery. Nanosensors can detect molecular fingerprints in the tumor micro environment even at low concentrations because of their electrochemical and mechanical properties, which improve the signal-to-noise ratio in biomarker detection. As a result, AI can assist in identifying several biomarkers that may be used to create a unique illness profile utilising sophisticated computational analysis [12].

DRUG DELIVERY USING NANOROBOTS AND SOPHISTICATED AI SOLUTIONS

Incorporating intelligent sensors, power supply, and artificial intelligence into nanorobots is advancing rapidly due to engineering and bio nanotechnology's remarkable advances. Additionally, researchers are examining the viability of automating AI-based molecular manufacturing regulates the behavior and movement of nanorobots. Since the neural network enhances prediction skills and optimizes efficiency for identifying cancer cells for targeted medication administration, ANNs are regarded as crucial parts of these nanorobots. Fuzzy logic has been identified as an effective method for estimating drug dosage for intracellular delivery following the diagnosis of a tumor, while the impact of AI on nanorobots has been highlighted [13].

Future Perspectives and Utilizing Novel Technologies and Artificial Intelligence to Address Nanoparticle-mediated Drug Delivery Obstacles

Continuous technological advancements have resulted in the development of cutting-edge techniques, such as artificial intelligence, that are promising for drug discovery and optimisation. Despite its numerous benefits, nanomedicine faces a variety of obstacles. The most commonly mentioned barriers are the EPR effect, size and type of drug delivery systems, problems with drug reservoir design, biocompatibility, drug concentrations, and toxicity. When concentrating on nanorobots for future theranostic applications, fabrication issues are an additional crucial factor. The capacity of these AI systems to learn from their surroundings and rely less on datasets is the main justification. A method for supervised learning that can distinguish between healthy and ill patient profiles and locate missing characteristics from datasets was recently suggested in research [14]. However, obstacles include high computational capacity, reliability of AI-enabled results, availability, maintenance, and ethical issues. Another common problem is the lack of large datasets with different types of clinical data for training AI models and optimizing for precise drug delivery [15]. However, in recent years, pharmaceutical and bioinformatics sectors have emerged as some of the next fields where effective AI integration has been actively noticed. Currently, AI is not widely used for medication development and delivery. Despite these difficulties, researchers have found that AI is accelerating medication development, including real-world tests. Additionally, gene treatments and the use of AI in regenerative medicine are also being studied. Like how medication delivery has been constrained by AI, future therapeutic uses of AI show potential for improving drug delivery.

DEVICE DEVELOPMENT AND APPROVAL PROCESS

India

Step 1: Discovery and concept of the device

It is essential to comprehend how devices are classified because the development process varies based on the classification of the device. Manufacturers must demonstrate device safety and efficacy to earn this.

Step 2:Preclinical Research-Prototype

Step 3:Route to Approval

Step 4: FDA(Food and Drug Administration) Device Review

Step 5: FDA Post-Market Monitoring of Device Safety

EU(European Union)

Medical gadgets are products or equipment created specifically for medical purposes. In order to demonstrate that they follow the regulations, are secure, and perform as intended, they must go through a conformity assessment in the European Union (EU). Despite being involved in the regulatory process, the European Medicines Agency (EMA) is governed at the level of EU Member States. Medical equipment that include in vitro diagnostics come under a distinct regulation category for which the EMA is responsible.

USA

The graphic, which can be downloaded from the Regulatory Affairs Management Suite (RAMS), details the FDA approval procedure for several types of devices in the United States. The essential registration stages are just briefly described here in this simplified overview.

Step 1: By using the FDA classification database, you may look up the classification of your device.

Step 2: Create a quality management system (QMS) in accordance with the FDA Quality System Regulation (QSR), where necessary, based on the classification of your device.

Step 3: Prepare and submit a 510(k) application or a premarket approval (PMA) application based on the device classification, together with the required application fee.

Step 4: The FDA performs facilities inspections of the producer and all significant suppliers engaged in the design and manufacturing of high-risk devices.

Step 5: The FDA evaluates the application and could ask for further details.

Step 6: Designate a U.S. Agent as your local point of contact with the FDA if you don't already have one.

Step 7: Using the FDA Unified Registration and Listing System (FURLS), register your business on the FDA website, list your device, and pay the applicable establishment registration and device listing costs.

CONCLUSION

The field of nanomedicine is expanding swiftly, and several drug carriers are being examined for their effectiveness in delivering drugs locally and to specific tumor locations. To increase the efficacy of cancer patients' treatments, hybrid approaches and nanotherapies are also constantly being tried. Understanding pharmacological synergies is important but establishing the effectiveness of targeted medicine delivery today depends heavily on patient profiles that are particular to them based on their molecular fingerprints. These are essential since the incidence of treatment failures and poor treatment response is still quite high. More clinical indicators are also needed to reduce treatment failures and the likelihood of cancer recurrence to enhance cancer therapies. In this situation, clever computational models are capable of properly processing complicated data and delivering precise outcomes. Consequently, the ability to classify patients based on molecular signatures, provide actionable insights on treatment response, the capacity to quantify clinical information, and, most importantly, contribute to image-guided drug delivery due to demonstrated capabilities with clinical imaging even in the case of RA and DM, all play crucial roles in the development of a road map to assess real-time monitoring of drug delivery procedures. Despite the fact that numerous techniques have been evaluated in the pharmaceutical and nanotechnology fields over the years, few studies have focused on AI for targeted drug delivery. In order to improve the efficacy of nanotechnology-based therapeutics, the purpose of this review was to outline how AI might be used to help overcome some of the limits of manufacturing processes and what effect it will likely have on cancer biomarker detection, patient profiling, and nanoparticle imaging and drug approval process for devices in India, EU and USA are described in brief.

REFERENCES

1. Kumar A, Sharipov M, Turaev A, Azizov S, Azizov I, Makhado E, et al. Polymer-Based hybrid nanoarchitectures for cancer therapy applications. *Polymers (Basel)*. (2022) 14(15):3027. doi: 10.3390/polym14153027
2. Qindeel M, Sargazi S, Hosseinikhah SM, Rahdar A, Barani M, Thakur VK, et al. Porphyrin-based nanostructures for cancer theranostics: chemistry: fundamentals and recent advances. *Chemistry Select*. (2021) 6(48):14082–99. doi: 10.1002/slct.202103418.
3. Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-Based drug delivery system: a patient-friendly chemotherapy for oncology. *Dose Response*. (2020) 18(3):1559325820936161. doi: 10.1177/1559325820936161

4. Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J, Shainsky-Roitman J, Lammers T, Schroeder A. Integrating artificial intelligence and nanotechnology for precision cancer medicine. *Advanced Materials*. 2020 Apr;32(13):1901989.
5. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21. PMID: 33099022; PMCID: PMC7577280.
6. Veselov VV, Nosyrev AE, Jicsinszky L, Alyautdin RN, Cravotto G. Targeted delivery methods for anticancer drugs. *Cancers (Basel)*. (2022) 14(3):622. doi: 10.3390/cancers14030622.
7. Liu X, Jiang J, Meng H. Transcytosis - an effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery. *Theranostics*. (2019) 9(26):8018–25. doi: 10.7150/thno.38587
8. Alomrani A., Badran M., Harisa G. I., ALshehry M., Alshamsan A., Alkholief M., et al. The Use of Chitosan-Coated Flexible Liposomes as a Remarkable Carrier to Enhance the Antitumor Efficacy of 5-fluorouracil against Colorectal Cancer. *Saudi Pharm. J.* 2019, 27, 603–611.
9. Aydın B., Uçar E., Tekin V., İçhedef Ç., Teksöz S. Biocompatible Delivery System for Metformin: Characterization, Radiolabeling and *In Vitro* Studies. *Anticancer Agents Med. Chem.* 2020,20, 1626–1634.
10. Bai J., Duan J., Liu R., Du Y., Luo Q., Cui Y., et al. Engineered Targeting tLyp-1 Exosomes as Gene Therapy Vectors for Efficient Delivery of siRNA into Lung Cancer Cells. *Asian J. Pharm. Sci.* 2020, 15, 461–471.
11. Das KP and J C (2023) Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Front. Med. Technol.* 4:1067144. doi: 10.3389/fmedt.2022.1067144
12. Zohuri B. Artificial intelligence integration with nanotechnology. *JBGSR*. (2020) 6(3). Available at: <https://biogenericpublishers.com/jbgsr.ms.id.00147.text/> (cited September 23, 2022). doi: 10.46718/JBGSR.2020.06.000147
13. Priyom Bose. Optimizing Drug Delivery Using AI [Internet]. *News-Medical.net*. (2022) [cited 2022 Oct 5]. Available from: <https://www.azolifesciences.com/article/Optimizing-Drug-Delivery-Using-AI.aspx>.
14. Midtvedt B, Olsén E, Eklund F, Höök F, Adiels CB, Volpe G, et al. Fast and accurate nanoparticle characterization using deep-learning-enhanced off-axis holography. *ACS Nano*. (2021) 15(2):2240–50. doi: 10.1021/acsnano.0c06902
15. Li J, Dekanovsky L, Khezri B, Wu B, Zhou H, Sofer Z. Biohybrid micro- and nanorobots for intelligent drug delivery. *Cyborg Bionic Systems*. (2022) 2022:13. Article ID: 9824057. doi: 10.34133/2022/9824057